Stockholders' Equity - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands			12 Months Ended
	Jun. 01, 2022	Oct. 20, 2021	Dec. 31, 2022	Dec. 31, 2021	Oct. 21, 2021
Subsidiary or Equity Method Investee [Line Items]
Preferred stock, shares authorized			5,000,000	5,000,000	5,000,000
Preferred stock, par value			$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized			100,000,000	100,000,000	100,000,000
Common stock, par value			$ 0.001	$ 0.001	$ 0.001
Aggregate intrinsic value of common stock exercised			$ 100	$ 1,800
Fair value of options vested			$ 4,400	$ 6,000
Weighted average grant date fair value			$ 1.22	$ 8.18
Unrecognized stock-based compensation expense			$ 4,600
Repurchase of common stock			0	0
Shares subject to repurchase			188,025	377,709
Aggregate exercise prices of early exercised shares			$ 100	$ 200
Unrecognized stock-based compensation expense, weighted-average recognition period			2 years 2 months 12 days
Common stock available for future grants			374,099	1,934,095
Dividend rate			0.00%	0.00%
Expected term			6 years
Compensation expense			$ 6,978	$ 6,817
Restricted Stock Units
Subsidiary or Equity Method Investee [Line Items]
Granted			1,485,629
Unrecognized stock-based compensation expense			$ 2,200	$ 1,900
Unrecognized stock-based compensation expense, weighted-average recognition period			2 years 10 months 24 days	1 year
Compensation expense			$ 2,727	$ 95
ESPP
Subsidiary or Equity Method Investee [Line Items]
Unrecognized stock-based compensation expense			$ 400
Unrecognized stock-based compensation expense, weighted-average recognition period			9 months 18 days
Common stock available for future grants		401,164
Maximum percentage of eligible compensation		15.00%
Purchase of common stock grant date share value		$ 25,000
Purchase price of common stock, percentage		85.00%
Compensation expense			$ 300
Shares purchased by participants			401,102
Percentage of exercise price discount rate	15.00%
ESPP | Tranche One
Subsidiary or Equity Method Investee [Line Items]
Risk-free interest rate	2.15%
Dividend rate	0.00%
Expected term	6 months
Volatility	74.52%
ESPP | Tranche Two
Subsidiary or Equity Method Investee [Line Items]
Risk-free interest rate	2.15%
Dividend rate	0.00%
Expected term	1 year
Volatility	65.14%
2008 Stock Plan
Subsidiary or Equity Method Investee [Line Items]
Share-based Compensation arrangement by share-based payment award, award vesting period			10 years
Share based compensation arrangement by share based payment award ratably thereafter vesting period			36 months
Percentage of vesting rights			25.00%
Vesting period			1 year
2021 Plan
Subsidiary or Equity Method Investee [Line Items]
Share-based Compensation arrangement by share-based payment award, award vesting period			10 years
Share based compensation arrangement by share based payment award ratably thereafter vesting period			36 months
Percentage of vesting rights			25.00%
Vesting period			1 year
Granted			1,485,629
Maximum
Subsidiary or Equity Method Investee [Line Items]
Expected term				6 years
Maximum | ESPP
Subsidiary or Equity Method Investee [Line Items]
Purchase shares of common stock		10,000
Maximum | 2008 Stock Plan
Subsidiary or Equity Method Investee [Line Items]
Exercise price, percent of estimated fair value of shares on date of grant			110.00%
Exercise price, percent of estimated fair market value of shares on date of grant			100.00%
Maximum | 2021 Plan
Subsidiary or Equity Method Investee [Line Items]
Exercise price, percent of estimated fair value of shares on date of grant			110.00%
Exercise price, percent of estimated fair market value of shares on date of grant			100.00%
Minimum
Subsidiary or Equity Method Investee [Line Items]
Expected term				5 years
Minimum | 2008 Stock Plan
Subsidiary or Equity Method Investee [Line Items]
Estimated fair value shares date of grant			10.00%
Minimum | 2021 Plan
Subsidiary or Equity Method Investee [Line Items]
Estimated fair value shares date of grant			10.00%